Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Birgitte B. Rasmussen, Meredith M. Regan, Anne E. Lykkesfeldt, Patrizia Dell'Orto, Barbara Del Curto, Katrine L. Henriksen, Mauro G. Mastropasqua, Karen N. Price, Eliane Méry, Magali Lacroix-Triki, Stephen Braye, Hans J. Altermatt, Richard D. Gelber, Monica Castiglione-Gertsch, Aron Goldhirsch, Barry A. Gusterson, Beat Thürlimann, Alan S. Coates, Giuseppe Viale

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III trial) has shown that letrozole significantly improves disease-free survival (DFS) compared with tamoxifen in postmenopausal women with endocrine-responsive early breast cancer. Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours. Methods: The BIG 1-98 trial consists of four treatment groups that compare 5 years of monotherapy with letrozole or tamoxifen, and sequential administration of one drug for 2 years followed by the other drug for 3 years. Our study includes data from the 4922 patients randomly assigned to the two monotherapy treatment groups (letrozole or tamoxifen for 5 years; 51 months median follow-up [range

Original languageEnglish
Pages (from-to)23-28
Number of pages6
JournalThe Lancet Oncology
Volume9
Issue number1
DOIs
Publication statusPublished - Jan 2008

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial'. Together they form a unique fingerprint.

Cite this